Compare Stocks: GLUE, CRSP, ACAD, and DYN

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACAD ACADIA Pharmaceuticals	$28.89 +2.3%	$25.14	$19.69 ▼ $29.85	$4.98B	0.81	1.67 million shs	559,317 shs
CRSP CRISPR Therapeutics	$54.12 +1.1%	$52.41	$44.12 ▼ $78.48	$5.23B	1.74	1.77 million shs	629,064 shs
DYN Dyne Therapeutics	$26.26 +2.2%	$22.83	$11.65 ▼ $27.31	$4.90B	1.07	2.10 million shs	672,918 shs
GLUE Monte Rosa Therapeutics	$15.49 -0.1%	$20.33	$4.30 ▼ $25.77	$1.32B	1.59	1.38 million shs	422,391 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACAD ACADIA Pharmaceuticals	0.00%	-3.32%	+10.31%	+36.49%	+11.49%
CRSP CRISPR Therapeutics	0.00%	+0.06%	+12.08%	+10.28%	-10.35%
DYN Dyne Therapeutics	0.00%	-2.10%	+8.26%	+55.38%	+107.59%
GLUE Monte Rosa Therapeutics	0.00%	-2.39%	-36.89%	-13.94%	+238.43%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACAD ACADIA Pharmaceuticals	$28.89 +2.3%	$25.14	$19.69 ▼ $29.85	$4.98B	0.81	1.67 million shs	559,317 shs
CRSP CRISPR Therapeutics	$54.12 +1.1%	$52.41	$44.12 ▼ $78.48	$5.23B	1.74	1.77 million shs	629,064 shs
DYN Dyne Therapeutics	$26.26 +2.2%	$22.83	$11.65 ▼ $27.31	$4.90B	1.07	2.10 million shs	672,918 shs
GLUE Monte Rosa Therapeutics	$15.49 -0.1%	$20.33	$4.30 ▼ $25.77	$1.32B	1.59	1.38 million shs	422,391 shs

7 Energy Stocks to Buy and Hold Forever

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACAD ACADIA Pharmaceuticals	0.00%	-3.32%	+10.31%	+36.49%	+11.49%
CRSP CRISPR Therapeutics	0.00%	+0.06%	+12.08%	+10.28%	-10.35%
DYN Dyne Therapeutics	0.00%	-2.10%	+8.26%	+55.38%	+107.59%
GLUE Monte Rosa Therapeutics	0.00%	-2.39%	-36.89%	-13.94%	+238.43%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACAD ACADIA Pharmaceuticals	2.82	Moderate Buy	$34.19	18.36% Upside
CRSP CRISPR Therapeutics	2.58	Moderate Buy	$68.06	25.75% Upside
DYN Dyne Therapeutics	2.87	Moderate Buy	$34.42	31.06% Upside
GLUE Monte Rosa Therapeutics	2.67	Moderate Buy	$28.50	83.99% Upside

Current Analyst Ratings Breakdown

Latest GLUE, CRSP, ACAD, and DYN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/17/2026	ACAD ACADIA Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$45.00 ➝ $49.00
8/17/2026	DYN Dyne Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$50.00
8/12/2026	ACAD ACADIA Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C) ➝ Hold (C+)
8/12/2026	ACAD ACADIA Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$38.00 ➝ $41.00
8/11/2026	GLUE Monte Rosa Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D+) ➝ Sell (D)
8/10/2026	ACAD ACADIA Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$27.00
8/10/2026	ACAD ACADIA Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$35.00 ➝ $39.00
8/7/2026	GLUE Monte Rosa Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$35.00 ➝ $28.00
8/7/2026	GLUE Monte Rosa Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$31.00 ➝ $27.00
8/7/2026	GLUE Monte Rosa Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$29.00 ➝ $27.00
8/6/2026	CRSP CRISPR Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral	$55.00

(Data available from 8/17/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACAD ACADIA Pharmaceuticals	$1.07B	4.65	$0.91 per share	31.83	$7.25 per share	3.98
CRSP CRISPR Therapeutics	$3.51M	1,490.84	N/A	N/A	$20.17 per share	2.68
DYN Dyne Therapeutics	N/A	N/A	N/A	N/A	$6.81 per share	N/A
GLUE Monte Rosa Therapeutics	$123.67M	10.69	N/A	N/A	$3.58 per share	4.33

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACAD ACADIA Pharmaceuticals	$391M	$2.22	13.01	30.41	22.24	33.42%	9.03%	6.79%	11/4/2026 (Estimated)
CRSP CRISPR Therapeutics	-$581.60M	-$4.76	N/A	N/A	N/A	-3,368.72%	-24.39%	-18.25%	N/A
DYN Dyne Therapeutics	-$446.21M	-$3.33	N/A	N/A	N/A	N/A	-64.30%	-50.33%	11/4/2026 (Estimated)
GLUE Monte Rosa Therapeutics	-$38.63M	-$1.76	N/A	N/A	N/A	-560.85%	-43.31%	-27.59%	11/5/2026 (Estimated)

Latest GLUE, CRSP, ACAD, and DYN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	GLUE Monte Rosa Therapeutics	-$0.3805	-$0.43	-$0.0495	-$0.43	$12.91 million	$8.97 million
8/4/2026	Q2 2026	ACAD ACADIA Pharmaceuticals	$0.0682	$0.18	+$0.1119	$0.18	$296.55 million	$308.00 million
8/3/2026	Q2 2026	CRSP CRISPR Therapeutics	-$1.19	-$0.94	+$0.25	-$0.94	$7.45 million	$10.18 million
7/30/2026	Q2 2026	DYN Dyne Therapeutics	-$0.7488	-$1.08	-$0.3312	-$1.08	N/A	N/A
6/30/2026	Q2 2026	CRSP CRISPR Therapeutics	N/A	-$0.94	N/A	-$0.94	N/A	$10.18 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACAD ACADIA Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CRSP CRISPR Therapeutics	N/A	N/A	N/A	N/A	N/A
DYN Dyne Therapeutics	N/A	N/A	N/A	N/A	N/A
GLUE Monte Rosa Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACAD ACADIA Pharmaceuticals	N/A	3.39	3.30
CRSP CRISPR Therapeutics	0.34	17.85	17.85
DYN Dyne Therapeutics	0.28	12.02	12.02
GLUE Monte Rosa Therapeutics	N/A	10.58	10.58

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACAD ACADIA Pharmaceuticals	96.71%
CRSP CRISPR Therapeutics	69.20%
DYN Dyne Therapeutics	96.68%
GLUE Monte Rosa Therapeutics	79.96%

Insider Ownership

Company	Insider Ownership
ACAD ACADIA Pharmaceuticals	26.20%
CRSP CRISPR Therapeutics	5.20%
DYN Dyne Therapeutics	9.46%
GLUE Monte Rosa Therapeutics	6.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACAD ACADIA Pharmaceuticals	510	172.31 million	127.16 million	Optionable
CRSP CRISPR Therapeutics	460	96.69 million	91.67 million	Optionable
DYN Dyne Therapeutics	100	186.75 million	169.08 million	Optionable
GLUE Monte Rosa Therapeutics	90	85.31 million	79.85 million	Optionable

GLUE, CRSP, ACAD, and DYN Headlines

Recent News About These Companies

JPMorgan Chase & Co. Cuts Monte Rosa Therapeutics (NASDAQ:GLUE) Price Target to $27.00

August 10, 2026 | americanbankingnews.com

Wells Fargo & Company Cuts Monte Rosa Therapeutics (NASDAQ:GLUE) Price Target to $27.00

August 10, 2026 | americanbankingnews.com

Monte Rosa Therapeutics (NASDAQ:GLUE) Announces Earnings Results

August 8, 2026 | marketbeat.com

The Manufacturers Life Insurance Company Raises Stake in Monte Rosa Therapeutics, Inc. $GLUE

August 8, 2026 | marketbeat.com

Dimensional Fund Advisors LP Acquires 473,005 Shares of Monte Rosa Therapeutics, Inc. $GLUE

August 8, 2026 | marketbeat.com

JPMorgan Chase & Co. Has Lowered Expectations for Monte Rosa Therapeutics (NASDAQ:GLUE) Stock Price

August 7, 2026 | marketbeat.com

Wells Fargo & Company Lowers Monte Rosa Therapeutics (NASDAQ:GLUE) Price Target to $27.00

August 7, 2026 | marketbeat.com

Monte Rosa Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates

August 6, 2026 | finance.yahoo.com

Monte Rosa Therapeutics (GLUE) Reports Q2 Loss, Misses Revenue Estimates

August 6, 2026 | zacks.com

Zacks Research Upgrades Monte Rosa Therapeutics (NASDAQ:GLUE) to "Hold"

August 6, 2026 | marketbeat.com

Janus Henderson Group PLC Invests $11.29 Million in Monte Rosa Therapeutics, Inc. $GLUE

August 5, 2026 | marketbeat.com

Renaissance Technologies LLC Makes New Investment in Monte Rosa Therapeutics, Inc. $GLUE

August 5, 2026 | marketbeat.com

Monte Rosa’s MODeFIRe-1 Trial Pushes GLUE Into a Key Mid-Stage Prostate Cancer Test

August 4, 2026 | tipranks.com

Monte Rosa Therapeutics (NASDAQ:GLUE) Shares Down 4.1% After Analyst Downgrade

August 3, 2026 | marketbeat.com

Monte Rosa Therapeutics (NASDAQ:GLUE) Price Target Lowered to $27.00 at Wedbush

August 3, 2026 | marketbeat.com

Swiss National Bank Invests $1 Million in Monte Rosa Therapeutics, Inc. $GLUE

August 1, 2026 | marketbeat.com

Arrowstreet Capital Limited Partnership Acquires 340,088 Shares of Monte Rosa Therapeutics, Inc. $GLUE

August 1, 2026 | marketbeat.com

Monte Rosa, BioAge plunge as Novo’s setback casts a shadow over pipeline

July 31, 2026 | seekingalpha.com

Monte Rosa Therapeutics (NASDAQ:GLUE) Shares Gap Down - Should You Sell?

July 31, 2026 | marketbeat.com

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Given Consensus Recommendation of "Moderate Buy" by Analysts

July 30, 2026 | marketbeat.com

Monte Rosa Therapeutics (GLUE) to Release Earnings on Thursday

July 30, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

GLUE, CRSP, ACAD, and DYN Company Descriptions

ACADIA Pharmaceuticals NASDAQ:ACAD

$28.89 +0.65 (+2.30%)

As of 03:15 PM Eastern

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

CRISPR Therapeutics NASDAQ:CRSP

$54.12 +0.57 (+1.06%)

As of 03:15 PM Eastern

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.

Dyne Therapeutics NASDAQ:DYN

$26.26 +0.56 (+2.18%)

As of 03:15 PM Eastern

Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.

Monte Rosa Therapeutics NASDAQ:GLUE

$15.49 -0.01 (-0.06%)

As of 03:15 PM Eastern

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest GLUE, CRSP, ACAD, and DYN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest GLUE, CRSP, ACAD, and DYN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

GLUE, CRSP, ACAD, and DYN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

GLUE, CRSP, ACAD, and DYN Company Descriptions

ACADIA Pharmaceuticals NASDAQ:ACAD

CRISPR Therapeutics NASDAQ:CRSP

Dyne Therapeutics NASDAQ:DYN

Monte Rosa Therapeutics NASDAQ:GLUE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest GLUE, CRSP, ACAD, and DYN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest GLUE, CRSP, ACAD, and DYN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

GLUE, CRSP, ACAD, and DYN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

GLUE, CRSP, ACAD, and DYN Company Descriptions

ACADIA Pharmaceuticals NASDAQ:ACAD

CRISPR Therapeutics NASDAQ:CRSP

Dyne Therapeutics NASDAQ:DYN

Monte Rosa Therapeutics NASDAQ:GLUE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools